Table 2 Clinicopathological features of patients with PTC
From: HIF-1α and Caspase-3 expression in aggressive papillary thyroid carcinoma
Variable | HIF-1α expression, n (%) | p-value | caspase-3 expression, n (%) | p-value | ||
|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | |||
Number | 42 (60) | 28 (40) | 26 (37.1) | 44 (62.9) | ||
Gender | 0.650 | 0.978 | ||||
Female | 36 (62.1) | 22 (37.9) | 21 (36.2) | 37 (63.8) | ||
Male | 6 (50.0) | 6 (50.0) | 5 (41.7) | 7 (58.3) | ||
Age (year) | 0.557 | 0.660 | ||||
< 45 | 24 (63.2) | 14 (36.8) | 15 (39.5) | 23 (60.5) | ||
≥ 45 | 18 (56.2) | 14 (43.8) | 11 (34.4) | 21 (65.6) | ||
Tumor size (cm) | 0.626 | 0.322 | ||||
< 1 | 22 (62.9) | 13 (37.1) | 11 (31.4) | 24 (68.6) | ||
≥ 1 | 20 (57.1) | 15 (42.9) | 15 (42.9) | 20 (57.1) | ||
Capsule invasion | 0.027* | 0.247 | ||||
Yes | 33 (68.8) | 15 (31.2) | 20 (41.7) | 28 (58.3) | ||
No | 9 (40.9) | 13 (59.1) | 6 (27.3) | 16 (72.7) | ||
CLNM | 0.768 | 0.083 | ||||
Yes | 18 (58.1) | 13 (41.9) | 15 (48.4) | 16 (51.6) | ||
No | 24 (61.5) | 15 (38.5) | 11 (28.2) | 28 (71.8) | ||
BRAFV600Emutation | 17 (73.9) | 6 (26.1) | 0.096 | 9 (39.1) | 14 (60.9) | 0.810 |
PTC subtype | 0.238 | 0.014* | ||||
FVPTC | 20 (58.8) | 14 (41.2) | 7 (20.6) | 27 (79.4) | ||
CVPTC | 13 (52.0) | 12 (48.0) | 12 (48.0) | 13 (52.0) | ||
TCV | 9 (81.8) | 2 (18.2) | 7 (63.6) | 4 (36.4) | ||